IL139285A0 - Peg-lhrh analog conjugates, their preparation and use - Google Patents
Peg-lhrh analog conjugates, their preparation and useInfo
- Publication number
- IL139285A0 IL139285A0 IL13928599A IL13928599A IL139285A0 IL 139285 A0 IL139285 A0 IL 139285A0 IL 13928599 A IL13928599 A IL 13928599A IL 13928599 A IL13928599 A IL 13928599A IL 139285 A0 IL139285 A0 IL 139285A0
- Authority
- IL
- Israel
- Prior art keywords
- peg
- lhrh analog
- preparation
- conjugates
- analog conjugates
- Prior art date
Links
- 239000002434 gonadorelin derivative Substances 0.000 title abstract 4
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical class C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 abstract 2
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8334098P | 1998-04-28 | 1998-04-28 | |
| PCT/US1999/009160 WO1999055376A1 (en) | 1998-04-28 | 1999-04-28 | Peg-lhrh analog conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL139285A0 true IL139285A0 (en) | 2001-11-25 |
Family
ID=22177691
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL13928599A IL139285A0 (en) | 1998-04-28 | 1999-04-28 | Peg-lhrh analog conjugates, their preparation and use |
| IL139285A IL139285A (en) | 1998-04-28 | 2000-10-26 | Peg-lhrh analog conjugates, their preparation and use |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL139285A IL139285A (en) | 1998-04-28 | 2000-10-26 | Peg-lhrh analog conjugates, their preparation and use |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US6433135B1 (de) |
| EP (1) | EP1075282B1 (de) |
| JP (1) | JP2002512982A (de) |
| AT (2) | ATE297762T1 (de) |
| AU (1) | AU760381B2 (de) |
| CA (1) | CA2330448A1 (de) |
| DE (2) | DE69939036D1 (de) |
| DK (1) | DK1075282T3 (de) |
| ES (2) | ES2242396T3 (de) |
| IL (2) | IL139285A0 (de) |
| PT (1) | PT1075282E (de) |
| WO (1) | WO1999055376A1 (de) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE469166T1 (de) * | 1997-06-06 | 2010-06-15 | Kyowa Hakko Kirin Co Ltd | Chemisch modifizierte polypeptide |
| ATE348163T1 (de) * | 1998-10-23 | 2007-01-15 | Amgen Inc | Thrombopoietin substitute |
| JP2002534363A (ja) | 1999-01-08 | 2002-10-15 | エミスフェアー・テクノロジーズ・インク | ポリマー性デリバリー剤及びデリバリー剤化合物 |
| EP1221975B1 (de) | 1999-10-04 | 2006-12-06 | Nektar Therapeutics Al, Corporation | Polymer-stabilisierte neuropeptide |
| PE20020376A1 (es) * | 2000-09-29 | 2002-05-13 | Abbott Lab | Polipeptidos antiangiogenicos y metodos para inhibir la angiogenesis |
| US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
| US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
| GB0202906D0 (en) | 2002-02-07 | 2002-03-27 | Univ London | Prevention of myocardial damage |
| ATE435035T1 (de) * | 2003-01-13 | 2009-07-15 | Bracco Imaging Spa | Verbesserte linker für radiopharmazeutische verbindungen |
| AU2004221824B2 (en) * | 2003-03-14 | 2009-08-27 | Ratiopharm Gmbh | Branched water-soluble polymers and their conjugates |
| CA2522345A1 (en) | 2003-04-09 | 2004-11-18 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
| US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
| US7932364B2 (en) | 2003-05-09 | 2011-04-26 | Novo Nordisk A/S | Compositions and methods for the preparation of human growth hormone glycosylation mutants |
| WO2005012484A2 (en) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
| US20050054752A1 (en) * | 2003-09-08 | 2005-03-10 | O'brien John P. | Peptide-based diblock and triblock dispersants and diblock polymers |
| DE602004029173D1 (de) | 2003-10-10 | 2010-10-28 | Novo Nordisk As | Il-21-derivate |
| US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
| US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
| US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
| NZ548123A (en) | 2004-01-08 | 2010-05-28 | Novo Nordisk As | O-linked glycosylation of peptides |
| EP1773400A2 (de) * | 2004-07-08 | 2007-04-18 | Amgen Inc. | Therapeutische peptide |
| WO2006010143A2 (en) | 2004-07-13 | 2006-01-26 | Neose Technologies, Inc. | Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1] |
| WO2006031811A2 (en) | 2004-09-10 | 2006-03-23 | Neose Technologies, Inc. | Glycopegylated interferon alpha |
| EP1814573B1 (de) | 2004-10-29 | 2016-03-09 | ratiopharm GmbH | Remodellierung und glykopegylierung von fibroblasten-wachstumsfaktor (fgf) |
| CA2594557C (en) * | 2004-12-22 | 2016-04-26 | Ambrx, Inc. | Modified human growth hormone |
| CA2593682C (en) | 2005-01-10 | 2016-03-22 | Neose Technologies, Inc. | Glycopegylated granulocyte colony stimulating factor |
| JP4877225B2 (ja) * | 2005-02-18 | 2012-02-15 | 日油株式会社 | ポリオキシアルキレン誘導体 |
| US9187546B2 (en) | 2005-04-08 | 2015-11-17 | Novo Nordisk A/S | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
| US20080255026A1 (en) | 2005-05-25 | 2008-10-16 | Glycopegylated Factor 1X | Glycopegylated Factor Ix |
| US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
| US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
| US20070238656A1 (en) * | 2006-04-10 | 2007-10-11 | Eastman Kodak Company | Functionalized poly(ethylene glycol) |
| US9283260B2 (en) | 2006-04-21 | 2016-03-15 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
| CN101516388B (zh) | 2006-07-21 | 2012-10-31 | 诺和诺德公司 | 通过o-联糖基化序列的肽的糖基化 |
| US8969532B2 (en) | 2006-10-03 | 2015-03-03 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography |
| EP2144923B1 (de) | 2007-04-03 | 2013-02-13 | BioGeneriX AG | Behandlungsverfahren mit glycopegyliertem g-csf |
| WO2008154639A2 (en) | 2007-06-12 | 2008-12-18 | Neose Technologies, Inc. | Improved process for the production of nucleotide sugars |
| US8207112B2 (en) | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
| WO2009075788A1 (en) * | 2007-12-05 | 2009-06-18 | Semprus Biociences Corporation | Synthetic non-fouling amino acids |
| US20130189239A1 (en) | 2008-02-27 | 2013-07-25 | Novo Nordisk A/S | Conjugated Factor VIII Molecules |
| US10166295B2 (en) | 2011-06-02 | 2019-01-01 | Opko Biologics Ltd. | Pegylated OXM variants |
| US8383093B1 (en) | 2011-11-01 | 2013-02-26 | Serina Therapeutics, Inc. | Subcutaneous delivery of poly(oxazoline) conjugates |
| MX362432B (es) | 2012-06-04 | 2019-01-17 | Opko Biologics Ltd | Variantes de oxm pegilada. |
| US12441776B2 (en) | 2018-11-30 | 2025-10-14 | Eirgen Pharma Ltd. | Oxyntomodulin peptide analog formulations |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4935491A (en) | 1987-08-24 | 1990-06-19 | Board Of Regents, The University Of Texas System | Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine |
| JPH03148298A (ja) * | 1989-11-01 | 1991-06-25 | Sumitomo Pharmaceut Co Ltd | 修飾ペプチドおよびその製造方法 |
| AU5006993A (en) * | 1992-08-21 | 1994-03-15 | Enzon, Inc. | Novel attachment of polyalkylene oxides to bio-effecting substances |
| US5449720A (en) * | 1993-05-24 | 1995-09-12 | Biotech Australia Pty Limited | Amplification of the VB12 uptake system using polymers |
| US5840900A (en) | 1993-10-20 | 1998-11-24 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| US5932462A (en) * | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US7953788B2 (en) * | 2001-09-29 | 2011-05-31 | Siebel Systems, Inc. | System and method for queuing data for an application server |
-
1999
- 1999-04-28 PT PT99921497T patent/PT1075282E/pt unknown
- 1999-04-28 DK DK99921497T patent/DK1075282T3/da active
- 1999-04-28 EP EP99921497A patent/EP1075282B1/de not_active Expired - Lifetime
- 1999-04-28 IL IL13928599A patent/IL139285A0/xx not_active IP Right Cessation
- 1999-04-28 ES ES99921497T patent/ES2242396T3/es not_active Expired - Lifetime
- 1999-04-28 ES ES05012776T patent/ES2309618T3/es not_active Expired - Lifetime
- 1999-04-28 AT AT99921497T patent/ATE297762T1/de not_active IP Right Cessation
- 1999-04-28 AT AT05012776T patent/ATE399567T1/de not_active IP Right Cessation
- 1999-04-28 DE DE69939036T patent/DE69939036D1/de not_active Expired - Fee Related
- 1999-04-28 DE DE69925830T patent/DE69925830T2/de not_active Expired - Fee Related
- 1999-04-28 CA CA002330448A patent/CA2330448A1/en not_active Abandoned
- 1999-04-28 AU AU38696/99A patent/AU760381B2/en not_active Ceased
- 1999-04-28 JP JP2000545573A patent/JP2002512982A/ja not_active Withdrawn
- 1999-04-28 WO PCT/US1999/009160 patent/WO1999055376A1/en not_active Ceased
-
2000
- 2000-10-26 IL IL139285A patent/IL139285A/en unknown
- 2000-10-30 US US09/698,134 patent/US6433135B1/en not_active Expired - Fee Related
-
2005
- 2005-05-24 US US11/135,475 patent/US7268210B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| IL139285A (en) | 2007-03-08 |
| US7268210B2 (en) | 2007-09-11 |
| CA2330448A1 (en) | 1999-11-04 |
| DE69925830T2 (de) | 2006-05-04 |
| AU760381B2 (en) | 2003-05-15 |
| WO1999055376A1 (en) | 1999-11-04 |
| EP1075282A1 (de) | 2001-02-14 |
| EP1075282B1 (de) | 2005-06-15 |
| US20050222214A1 (en) | 2005-10-06 |
| DK1075282T3 (da) | 2005-10-10 |
| ATE297762T1 (de) | 2005-07-15 |
| PT1075282E (pt) | 2005-09-30 |
| ATE399567T1 (de) | 2008-07-15 |
| JP2002512982A (ja) | 2002-05-08 |
| DE69925830D1 (de) | 2005-07-21 |
| ES2242396T3 (es) | 2005-11-01 |
| ES2309618T3 (es) | 2008-12-16 |
| US6433135B1 (en) | 2002-08-13 |
| DE69939036D1 (de) | 2008-08-14 |
| AU3869699A (en) | 1999-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69925830D1 (de) | Peg-lhrh analog konjugate | |
| IL112372A0 (en) | Non-viral vector | |
| GEP20053473B (en) | High Potency Dihydroergotamine Compositions | |
| UA103758C2 (ru) | Конъюгаты олигомеров инсулина, их композиции и применение | |
| WO1997044063A3 (en) | Dha-pharmaceutical agent conjugates | |
| WO2003022210A3 (en) | Pharmaceutical compositions of drug-oligomer conjugates and methods of treating diseases therewith | |
| NZ534618A (en) | The preparation and use of radium-223 to target calcified tissues for pain palliation, bone cancer therapy, and bone surface conditioning | |
| MX9700552A (es) | Conjugados de vitamina b12 y proteinas. | |
| TWI266800B (en) | Polyol-IFN-beta conjugates | |
| DE69835201D1 (en) | Neoglycoproteine | |
| IL133585A0 (en) | Soluble prodrugs of paclitaxel | |
| IL112664A0 (en) | 4-amino derivatives of mycophenolic acid, their preparation and pharmaceutical compositions containing them | |
| AP2001002187A0 (en) | Piperidines as CCR5 modulators. | |
| AU2002225772A1 (en) | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease | |
| WO1997029779A3 (en) | EGF-Genistein conjugates for the treatment of cancer | |
| MY118526A (en) | Method for improving the pharmacokinetics of tipranavir | |
| BG104436A (en) | The administration of macrolides for the treatment of cancer and macular degeneration | |
| HUP0100350A3 (en) | Conjugates useful in the treatment of prostate cancer, pharmaceutical compositions comprising thereof, process for their preparation and their use | |
| UA66856C2 (uk) | Тієнопіримідини, спосіб їх одержання, фармацевтична композиція та спосіб її одержання | |
| MY119090A (en) | Synthetic polysaccharides, process for their preparation and pharmaceutical compositions containing them | |
| BG102660A (en) | Combined pharmaceutical preparation of lhrh-analogues and antiesterogens for the treatment of gynaecological disorders | |
| WO2000053231A3 (en) | Fatty acid-anticancer conjugates and uses thereof | |
| BG105275A (en) | Tan-1057 derivatives | |
| BG104179A (en) | Phanquinon administration for the treatment of the alzheimer's disease | |
| ATE226065T1 (de) | Feste instant-release-darreichungsformen und verfahren zu ihrer herstellung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |